• BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

  Hall, E; Porta, N; Huddart, R; Cruickshank, C; Burnett, S; Maynard, L
• SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. 

  Boysen, G; Rodrigues, DN; Rescigno, P; Seed, G; Dolling, D; Riisnaes, R; Crespo, M; Zafeiriou, Z; Sumanasuriya, S; Bianchini, D; Hunt, J; Moloney, D; Perez-Lopez, R; Tunariu, N; Miranda, S; Figueiredo, I; Ferreira, A; Christova, R; Gil, V; Aziz, S; Bertan, C; de Oliveira, FM; Atkin, M; Clarke, M; Goodall, J; Sharp, A; MacDonald, T; Rubin, MA; Yuan, W; Barbieri, CE; Carreira, S; Mateo, J; de Bono, JS (2018-08-01)

  Purpose:CHD1 deletions and SPOP mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and ...
• 

  Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer 

  Wagner, S; Vlachogiannis, G; De Haven Brandon, A; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, A; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, C; Kirkin, V; Valeri, N; Whittaker, S
• Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies 

  Elnenaei, MO; Jadayel, DM; Matutes, E; Morilla, R; Owusu-Ankomah, K; Atkinson, S; Titley, I; Mandala, EM; Catovsky, D (2001)

  The translocation (11;14)(q13;q32) and its molecular counterpart the BCL-1 rearrangement are features observed in mantle cell lymphoma (MCL) and less commonly in other B-cell disorders. This rearrangement leads to cyclin ...
• t(2;5) associated with a histiocytic-monocytic neoplasm 

  Lemes, A; de la Iglesia, S; Santana, C; Cigudosa, JC; Matutes, E; Molero, T (2001-04)

  We describe a patient with a neoplasm derived from the histiocytic-monocytic lineage associated with t(2:5) detected by FISH. The patient presented with bone marrow involvement, no organomegaly and subsequently developed ...
• Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia 

  Tuset, E; Matutes, E; Brito-Babapulle, V; Morilla, R; Catovsky, D

  T-cell prolymphocytic leukaemia (T-PLL) is an aggressive disease often resistant to conventional chemotherapy. Long lasting remissions with the monoclonal antibody CAMPATH-1H (anti-CD52) have been documented. We describe ...
• Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients 

  Matutes, E; Taylor, GP; Cavenagh, J; Pagliuca, A; Bareford, D; Domingo, A; Hamblin, R; Kelsey, S; Mir, N; Reilly, JT (BLACKWELL SCIENCE LTD, 2001-06)

  Adult T-cell leukaemia lymphoma (ATLL) is an aggressive disease caused by the human T-lymphotropic virus 1 (HTLV-I) with a short survival, Responses to interferon alpha (IFN-alpha) and zidovudine (AZT) have been documented ...
• Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. 

  Sundar, R; McVeigh, T; Dolling, D; Petruckevitch, A; Diamantis, N; Ang, JE; Chenard-Poiriér, M; Collins, D; Lim, J; Ameratunga, M; Khan, K; Kaye, SB; Banerji, U; Lopez, J; George, AJ; de Bono, JS; van der Graaf, WT (2018-09)

  BACKGROUND: Adolescent and young adult (AYA) patients with advanced solid tumours are often considered for phase I clinical trials with novel agents. The outcome of AYAs in these trials have not been described before. AIM: ...
• Acute myeloid leukaemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients 

  Bene, MC; Bernier, M; Casasnovas, RO; Castoldi, G; Doekharan, D; van der Holt, B; Knapp, W; Lemez, P; Ludwig, WD; Matutes, E; Orfao, A; Schoch, C; Sperling, C; van t Veer, MB; Charact, EGI (2001-06)

  Haematological, immunophenotypic and cytogenetic characteristics were analysed in 241 patients with acute myeloid leukaemia (AML) M0, including 58 children. Children < 3 years and adults between 60 and 70 years of age were ...
• Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia 

  Brito-Babapulle, V; Baou, M; Matutes, E; Morilla, R; Atkinson, S; Catovsky, D (BLACKWELL SCIENCE LTD, 2001-08)

  Deletions of 13q14.3 are well known in several malignancies and are thought to be associated with tumour suppressor function. The RB-1 gene is a tumour suppressor gene, but other loci including D13S319 and D13S25 telomeric ...
• Comparative genomic hybridization and amplotyping by arbitrarily primed PCR in stage A B-CLL 

  Odero, MD; Soto, JL; Matutes, E; Martin-Subero, JI; Zudaire, I; Rao, PH; Cigudosa, JC; Ardanaz, MT; Chaganti, RSK; Perucho, M; Calasanz, MJ (2001-10-01)

  Cytogenetic analysis is useful in the diagnosis and to assess prognosis of B-cell chronic lymphocytic leukemia (B-CLL). However, successful cytogenetics by standard techniques has been hindered by the low in vitro mitotic ...
• Alemtuzumab in T-cell malignancies 

  Dearden, CE; Matutes, E; Catovsky, D (HUMANA PRESS INC, 2002)

  Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen, which is abundantly expressed on all normal and most malignant T-lymphocytes. We summarize the results of our experience using alemtuzumab ...
• Transformation of T-cell large granular lymphocyte leukaemia into a high-grade large T-cell lymphoma 

  Matutes, E; Wotherspoon, AC; Parker, NE; Osuji, N; Isaacson, PG; Catovsky, D (WILEY-BLACKWELL, 2001-12)

  We describe a case of T-cell large granular lymphocyte (LGL) leukaemia that transformed into a large-cell T-cell lymphoma 11 years from diagnosis. A 29-year-old asymptomatic female presented in 1989 with lymphocytosis, ...
• Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif 

  Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR (2002-01-17)

  The mature sporadic T-cell malignancy, T-cell prolymphocytic leukemia (T-PLL) is remarkable for frequently harbouring somatic mutations of the Ataxia Telangiectasia (A-T) gene, ATM. Because some data suggest ATM is frequently ...
• Response to cyclosporine in a patient with disseminated granuloma annulare associated with CD4(+)/CD8(+(dim))/CD56(+) large granular lymphocytic leukemia 

  Granjo, E; Lima, M; Lopes, JM; Fernandes, JC; Antunes, I; Candeias, J; Matutes, E (2002-02)
• 

  Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin’s lymphoma with leukemia 

  Brito-Babapulle, V; Gruszka-Westwood, AM; Platt, G; Andersen, CL; Elnenaei, MO; Matutes, E; Wotherspoon, AC; Weston-Smith, SG; Catovsky, D (2002-04)

  Background and Objectives. A female patient presented with splenomegaly and lymphocytosis with atypical lymphoid cell morphology, We identified t(2;7)(p12;q21) prompting studies of the translocation breakpoint and its ...
• Teaching cases from The Royal Marsden and St Mary’s Hospitals. Case 22: An unusual cause of lymphocytosis 

  Patel, KC; Bain, BJ; Matutes, E; Catovsky, D (2002-04)
• New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders 

  Matutes, E (2002-03)

  Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative ...
• Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders 

  Bain, BJ; Barnett, D; Linch, D; Matutes, E; Reilly, JT (BLACKWELL PUBLISHING LTD, 2002-02)
• CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease 

  Scolnik, MP; Morilla, R; Bracco, MMDED; Catovsky, D; Matutes, E (2002)

  We estimated by quantitative flow cytometry (FC) the expression of CD13, CD33, CD34 and CD117 antigens in cells from 64 patients with acute myeloid leukaemia (AML) and 22 normal bone marrows (BMs). The method converts ...

View more